NAYA Biosciences, Inc.
NAYA · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $1 | $2 |
| % Growth | -2.9% | 17.6% | -22% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | $1 | $1 | $0 | $1 |
| % Margin | 36.2% | 43.2% | 31% | 53.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3 | $3 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $15 | $1 | $0 | $0 |
| Operating Expenses | $18 | $5 | $2 | $3 |
| Operating Income | -$17 | -$4 | -$1 | -$2 |
| % Margin | -1,044.9% | -235.8% | -90.7% | -103.6% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$17 | -$4 | -$2 | -$2 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$17 | -$4 | -$2 | -$2 |
| % Margin | -1,063% | -214.9% | -113.8% | -122.2% |
| EPS | -56.22 | -9.04 | -5.04 | -0.622 |
| % Growth | -521.9% | -79.4% | -710.3% | – |
| EPS Diluted | -56.22 | -9.04 | -5.04 | -0.622 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 4 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$17 | -$3 | -$1 | -$2 |
| % Margin | -1,029.7% | -190.6% | -76.6% | -89.6% |